Table 4.

Multivariate Cox proportional hazard analysis predicting shorter progression‐free survival in patients with non‐small cell lung cancer treated with nivolumab

Variate	HR (95%CI)	P‐value
Age ≥75	0.84 (0.41–1.72)	0.631
Male gender	1.61 (0.74–3.50)	0.278
Heavy smoker	0.36 (0.18–0.75)	0.006
ECOG performance status ≥2	8.55 (3.09–23.7)	0.000
EGFR‐mutant	0.76 (0.26–2.15)	0.606
Squamous cell carcinoma	2.41 (1.24–2.15)	0.011
Interstitial septal thickening	2.48 (1.24–4.94)	0.010

CI, confidence interval; HR, hazard ratio.